ImmuPharma PLC Clinical Development Collaboration with Incanthera
ImmuPharma PLC (LON: IMM), the specialist drug discovery and development company provides an update in relation to its discussions with Incanthera Limited (“Incanthera”) on its Nucant cancer programme. Background On